001     169018
005     20240229133635.0
024 7 _ |a 10.1016/S1470-2045(21)00199-6
|2 doi
024 7 _ |a pmid:34048685
|2 pmid
024 7 _ |a 1470-2045
|2 ISSN
024 7 _ |a 1474-5488
|2 ISSN
024 7 _ |a altmetric:106426390
|2 altmetric
037 _ _ |a DKFZ-2021-01186
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Cardoso, Rafael
|0 P:(DE-HGF)0
|b 0
|e First author
245 _ _ |a Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study.
260 _ _ |a London
|c 2021
|b The Lancet Publ. Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1626333030_18178
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C120#LA:C070#/2021 Jul;22(7):1002-1013
520 _ _ |a Colorectal cancer screening programmes and uptake vary substantially across Europe. We aimed to compare changes over time in colorectal cancer incidence, mortality, and stage distribution in relation to colorectal cancer screening implementation in European countries.Data from nearly 3·1 million patients with colorectal cancer diagnosed from 2000 onwards (up to 2016 for most countries) were obtained from 21 European countries, and were used to analyse changes over time in age-standardised colorectal cancer incidence and stage distribution. The WHO mortality database was used to analyse changes over time in age-standardised colorectal cancer mortality over the same period for the 16 countries with nationwide data. Incidence rates were calculated for all sites of the colon and rectum combined, as well as the subsites proximal colon, distal colon, and rectum. Average annual percentage changes (AAPCs) in incidence and mortality were estimated and relevant patterns were descriptively analysed.In countries with long-standing programmes of screening colonoscopy and faecal tests (ie, Austria, the Czech Republic, and Germany), colorectal cancer incidence decreased substantially over time, with AAPCs ranging from -2·5% (95% CI -2·8 to -2·2) to -1·6% (-2·0 to -1·2) in men and from -2·4% (-2·7 to -2·1) to -1·3% (-1·7 to -0·9) in women. In countries where screening programmes were implemented during the study period, age-standardised colorectal cancer incidence either remained stable or increased up to the year screening was implemented. AAPCs for these countries ranged from -0·2% (95% CI -1·4 to 1·0) to 1·5% (1·1 to 1·8) in men and from -0·5% (-1·7 to 0·6) to 1·2% (0·8 to 1·5) in women. Where high screening coverage and uptake were rapidly achieved (ie, Denmark, the Netherlands, and Slovenia), age-standardised incidence rates initially increased but then subsequently decreased. Conversely, colorectal cancer incidence increased in most countries where no large-scale screening programmes were available (eg, Bulgaria, Estonia, Norway, and Ukraine), with AAPCs ranging from 0·3% (95% CI 0·1 to 0·5) to 1·9% (1·2 to 2·6) in men and from 0·6% (0·4 to 0·8) to 1·1% (0·8 to 1·4) in women. The largest decreases in colorectal cancer mortality were seen in countries with long-standing screening programmes.We observed divergent trends in colorectal cancer incidence, mortality, and stage distribution across European countries, which appear to be largely explained by different levels of colorectal cancer screening implementation.German Cancer Aid (Deutsche Krebshilfe) and the German Federal Ministry of Education and Research.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|x 0
|f POF IV
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Guo, Feng
|0 P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919
|b 1
|u dkfz
700 1 _ |a Heisser, Thomas
|0 P:(DE-He78)c465139c8b95a919efed7d35ca83ca80
|b 2
|u dkfz
700 1 _ |a Hackl, Monika
|b 3
700 1 _ |a Ihle, Petra
|b 4
700 1 _ |a De Schutter, Harlinde
|b 5
700 1 _ |a Van Damme, Nancy
|b 6
700 1 _ |a Valerianova, Zdravka
|b 7
700 1 _ |a Atanasov, Trajan
|b 8
700 1 _ |a Májek, Ondřej
|b 9
700 1 _ |a Mužík, Jan
|b 10
700 1 _ |a Nilbert, Mef Christina
|b 11
700 1 _ |a Tybjerg, Anne Julie
|b 12
700 1 _ |a Innos, Kaire
|b 13
700 1 _ |a Mägi, Margit
|b 14
700 1 _ |a Malila, Nea
|b 15
700 1 _ |a Bouvier, Anne-Marie
|b 16
700 1 _ |a Bouvier, Véronique
|b 17
700 1 _ |a Launoy, Guy
|b 18
700 1 _ |a Woronoff, Anne-Sophie
|b 19
700 1 _ |a Cariou, Mélanie
|b 20
700 1 _ |a Robaszkiewicz, Michel
|b 21
700 1 _ |a Delafosse, Patricia
|b 22
700 1 _ |a Poncet, Florence
|b 23
700 1 _ |a Katalinic, Alexander
|b 24
700 1 _ |a Walsh, Paul M
|b 25
700 1 _ |a Senore, Carlo
|b 26
700 1 _ |a Rosso, Stefano
|b 27
700 1 _ |a Vincerževskienė, Ieva
|b 28
700 1 _ |a Lemmens, Valery E P P
|b 29
700 1 _ |a Elferink, Marloes A G
|b 30
700 1 _ |a Johannesen, Tom Børge
|b 31
700 1 _ |a Kørner, Hartwig
|b 32
700 1 _ |a Pfeffer, Frank
|b 33
700 1 _ |a Bento, Maria José
|b 34
700 1 _ |a Rodrigues, Jessica
|b 35
700 1 _ |a Alves da Costa, Filipa
|b 36
700 1 _ |a Miranda, Ana
|b 37
700 1 _ |a Zadnik, Vesna
|b 38
700 1 _ |a Žagar, Tina
|b 39
700 1 _ |a Lopez de Munain Marques, Arantza
|b 40
700 1 _ |a Marcos-Gragera, Rafael
|b 41
700 1 _ |a Puigdemont, Montse
|b 42
700 1 _ |a Galceran, Jaume
|b 43
700 1 _ |a Carulla, Marià
|b 44
700 1 _ |a Chirlaque, María-Dolores
|b 45
700 1 _ |a Ballesta, Monica
|b 46
700 1 _ |a Sundquist, Kristina
|b 47
700 1 _ |a Sundquist, Jan
|b 48
700 1 _ |a Weber, Marco
|b 49
700 1 _ |a Jordan, Andrea
|b 50
700 1 _ |a Herrmann, Christian
|b 51
700 1 _ |a Mousavi, Mohsen
|b 52
700 1 _ |a Ryzhov, Anton
|b 53
700 1 _ |a Hoffmeister, Michael
|0 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
|b 54
|u dkfz
700 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 55
|e Last author
|u dkfz
773 _ _ |a 10.1016/S1470-2045(21)00199-6
|g p. S1470204521001996
|0 PERI:(DE-600)2035574-9
|n 7
|p 1002-1013
|t The lancet / Oncology
|v 22
|y 2021
|x 1470-2045
909 C O |o oai:inrepo02.dkfz.de:169018
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)0311ebf3415e41860b4e2c56fbae6919
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)c465139c8b95a919efed7d35ca83ca80
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 54
|6 P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 55
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b LANCET ONCOL : 2019
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-29
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b LANCET ONCOL : 2019
|d 2021-01-29
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 0
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21